Health TrialsbyHealthPanel

A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232

ConditionDiabetes Mellitus
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19+
SponsorAddpharma Inc.

About this trial

A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit

The Age equal to or greater than 19 in healthy volunteers at the time of screening visit

Disqualifiers

Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration

Other exclusions applied

Trial design

Design model

Crossover

Treatments tested in this trial

  • AD-123

    Drug

    AD-123 Oral Tablet

  • AD-1231 and AD-1232

    Drug

    AD-1231 Oral Tablet + AD-1232 Oral Tablet

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Sequence A (RT)Experimental treatment 2 interventions
Group B: Sequence B (TR)Experimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Maximum concentration of drug in plasma (Cmax)

Cmax of AD-123

Time frame
pre-dose to 72 hours
2

Area under the plasma concentration-time curve during dosing interval (AUCt)

AUCt of AD-123

Time frame
pre-dose to 72 hours

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Addpharma Inc.

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: